Ambrx Biopharma Inc

Ambrx Biopharma Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ambrx Biopharma, Inc. is a clinical-stage biologics company, which engages in discovering and developing a novel class of engineered precision biologics (EPBs). Using its proprietary expanded genetic code technology platform, it allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, and ARX305. The company was founded on August 11, 2023 and is headquartered in La Jolla, CA.

SAN DIEGO--( BUSINESS WIRE )--Ambrx Biopharma Inc. (Ambrx) (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics platform to create antibody drug conjugates, announced today that it received a notice (the Notice) on November 23, 2022 from the New York Stock Exchange (NYSE) that it was not in compliance with the NYSE's continued listing standards because the average closing price of Ambrx's American Depositary Shares (ADS), each representing seven ordinary shares, had fallen below $1.00 per ADS (Minimum Stock Price) over a period of 30 consecutive trading days, which is the minimum average closing price per ADS required to maintain continued listing on the NYSE.

Ambrx Biopharma Inc. Announces Receipt of NYSE Non-Compliance Letter Regarding ADS Trading Price

Cosmos Holdings

ComSovereign Holding

Use these tips for evaluating penny stocks to buy The post How to Find and Evaluate Penny Stocks For Your Portfolio  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Find and Evaluate Penny Stocks For Your Portfolio

In a topsy-turvy session today, investors may be intrigued by some of the biggest gainers and decliners as most stocks hold around the flat line. Among the leaders in terms of percentage gains today is biotech company Ambrx (NYSE: AMAM ), which has absolutely skyrocketed today.

Why Is Ambrx (AMAM) Stock Up 400% Today?

SAN DIEGO--( BUSINESS WIRE )--​Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody drug conjugates (ADCs), today announced preliminary safety and efficacy data from its Phase 2 ACE‑Breast-03 study during a Spotlight Poster Presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS). The data presented by the investigator demonstrated 51.7% overall response rate (ORR) by RECIST v1.1 and 100% disease control rate (DCR) after treatment with ARX788 in HER2 positive mBC patients who are resistant or refractory to T-DM1.

Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment

Investigators to present efficacy and safety data of ARX788 treatment in patients with HER2+ metastatic breast cancer who have progressed following treatment with T-DM1 Investigators to present efficacy and safety data of ARX788 treatment in patients with HER2+ metastatic breast cancer who have progressed following treatment with T-DM1

Interim Data from Ambrx's Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody drug conjugates (ADCs), today announced the first patient has been dosed by Ambrx's partner, NovoCodex Biopharmaceuticals, Inc. (NovoCodex) in its Phase 1 trial of ARX305 in patients with advanced solid tumors.

Ambrx Announces NovoCodex's Dosing of First Patient with ARX305, Ambrx's Investigational Antibody Drug Conjugate Targeting CD70

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Daniel O'Connor as Chief Executive Officer.

Ambrx Biopharma Inc. Appoints Daniel O'Connor as Chief Executive Officer

- Company now focused on earlier stage engineered antibody drugs for cancer therapies, including new lead asset ARX517 –

Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update

Conference call to discuss outcome of the strategic review that was initiated in August 2022 Conference call to discuss outcome of the strategic review that was initiated in August 2022

Ambrx Biopharma to Host Corporate Update Conference Call

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today provided a corporate update and reported financial results for the first half of 2022. "I am very grateful for all that Tian accomplished during his tenure leading Ambrx, from spearheading the development of the company's research and development programs to the transition to

Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Kate Hermans as interim Chief Executive Officer, replacing Feng Tian, Ph.D., effective immediately. Dr. Tian has agreed to remain available to the company in an advisory capacity. Ambrx's Board of Directors has commenced a search for a permanent C

Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointments of Edward Hu and Kate Hermans to its Board of Directors. “I am delighted to welcome both Edward and Kate to Ambrx's Board,” said Feng Tian, Ph. D., Chairman of the Board, President, and CEO of Ambrx. “Together, they have decades of experience in bus

Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced that Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx, will participate in the virtual H.C. Wainwright Preclinical Cancer Drug Discover: Emerging Targets and Modalities Conference on Wednesday, June 29, 2022. Dr. Tian will participate in a virtual

Ambrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover Conference

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Janet Loesberg, Pharm. D., to its Board of Directors. “I am pleased to welcome Janet as the newest director to Ambrx's Board,” said Feng Tian, Ph. D., Chairman of the Board, President, and CEO of Ambrx. “Janet brings with her more than three decad

Ambrx Biopharma Inc. Appoints Janet Loesberg to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced that Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx, will participate in two upcoming investor conferences in June. Cowen's 3rd Annual Oncology Innovation Summit. Dr. Tian will participate in an analyst led fireside chat on Thursday, June 2 at 1

Ambrx Biopharma Inc. to Participate in Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the appointment of Janice Lu, M.D., Ph.D., as Chief Medical Officer of Ambrx. Dr. Lu is a distinguished clinical professor of medicine who has more than 18 years of experience in leading clinical trials and breast cancer drug development. “I am delighted to welcome

Ambrx Biopharma Inc. Appoints Janice Lu, M.D., Ph.D., as Chief Medical Officer

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced that Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx, will present at two upcoming investor conferences in May. Bank of America 2022 Healthcare Conference. Dr. Tian will participate in an analyst led fireside chat on Wednesday, May 11 at 12:00 PM

Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced that it filed its annual report on Form 20-F (the “Form 20-F”) for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission (“SEC”) on April 26, 2022. The Form 20-F can be accessed by visiting either the SEC's website at www.sec.gov or the Company'

Ambrx Biopharma Inc. Announces Filing of Annual Report on Form 20-F

Ambrx Biopharma Inc. (NYSE:AMAM ) Q4 2021 Earnings Conference Call April 26, 2022 4:30 PM ET Company Participants Feng Tian – Chief Executive Officer Sonja Nelson – Chief Financial Officer Laurence Watts – Managing Director, Gilmartin Group Conference Call Participants Corinne Jenkins – Goldman Sachs Tazeen Ahmad – Bank of America Phil Nadeau – Cowen Joel Beatty – Baird Operator Welcome to the Ambrx Second Half and Full Year 2021 Financial Results and Corporate Update Conference Call. At this time, all participants are on listen-only mode.

Ambrx Biopharma Inc. (AMAM) CEO Feng Tian on Q4 2021 Results - Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today provided a corporate update and reported financial results for the full year ended December 31, 2021. “We have made great progress in advancing our engineered precision biologics and clinical pipeline in recent months. We continue to transition preclinical candidates into the clinic

Ambrx Biopharma Inc. Reports Full Year 2021 Financial Results; Provides Corporate Update

Quantum Leap Healthcare Collaborative and Ambrx Biopharma Inc (NYSE: AMAM) have announced the selection of Ambrx's antibody-drug conjugate (ADC) ARX788 for a new investigational treatment arm in the I-SPY 2.2 TRIAL. Sponsored by Quantum Leap, I-SPY 2.2 is an adaptive Phase.

Ambrx Biopharma's ARX788 Selected For Phase 2 Adaptive Breast Cancer Trial

SAN DIEGO--(BUSINESS WIRE)--Quantum Leap Healthcare Collaborative™ (Quantum Leap) and Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the selection of Ambrx's antibody drug conjugate (ADC) ARX788 for a new investigational treatment arm in the I-SPY 2.2 TRIAL for the treatment of HER2-positive breast cancer in the neoadjuvant setting. Sponsored by

Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of ARX788 in the I-SPY 2.2 Phase 2 Adaptive Clinical Trial for Breast Cancer

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced that the company will release full year 2021 financial results on Tuesday April 26, 2022 after the close of market. Ambrx will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corpor

Ambrx Biopharma Inc. to Release Full Year 2021 Financial Results on Tuesday, April 26, 2022

After losing some value lately, a hammer chart pattern has been formed for Ambrx Biopharma Inc. Sponsored ADR (AMAM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Ambrx Biopharma Inc. Sponsored ADR (AMAM) Could Find Support Soon, Here's Why You Should Buy the Stock Now

SAN DIEGO--(BUSINESS WIRE)--Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced that Feng Tian, Ph.D., Chairman of the Board, President, and CEO of Ambrx, will present at Oppenheimer's 32nd Annual Healthcare Conference taking place March 15-17, 2022. Dr. Tian is scheduled to present on Thursday, March 17, at 12:40 p.m. Eastern Time. Interested parties

News for Ambrx Biopharma Inc Stock (AMAM)